Immunome, Inc.
IMNM
$7.17
-$0.23-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -28.44% | -18.37% | -44.55% | -56.47% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.44% | -18.37% | -44.55% | -56.47% | -- |
| Cost of Revenue | 396.94% | 873.06% | 408.80% | 292.77% | 128.74% |
| Gross Profit | -677.01% | -13,190.70% | -1,738.89% | -825.76% | -37.93% |
| SG&A Expenses | 29.93% | 117.74% | 61.53% | 105.51% | 124.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 230.01% | 469.97% | 259.32% | 212.71% | 127.01% |
| Operating Income | -301.40% | -845.74% | -483.70% | -355.04% | -77.87% |
| Income Before Tax | 13.37% | -984.00% | -550.03% | -2,932.60% | -1,089.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.37% | -984.00% | -550.03% | -2,932.60% | -1,089.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.37% | -984.00% | -550.03% | -2,932.60% | -1,089.75% |
| EBIT | -301.40% | -845.74% | -483.70% | -355.04% | -77.87% |
| EBITDA | -302.54% | -859.86% | -484.41% | -361.23% | -78.11% |
| EPS Basic | 41.01% | -119.69% | -32.29% | -616.75% | -237.20% |
| Normalized Basic EPS | -204.34% | -88.45% | -9.17% | 2.92% | 56.93% |
| EPS Diluted | 40.84% | -119.69% | -32.29% | -616.75% | -236.20% |
| Normalized Diluted EPS | -204.34% | -88.45% | -9.17% | 2.92% | 56.93% |
| Average Basic Shares Outstanding | 46.85% | 393.39% | 391.37% | 323.10% | 252.82% |
| Average Diluted Shares Outstanding | 46.85% | 393.39% | 391.37% | 323.10% | 252.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |